OKYO Pharma Limited Ordinary Shares earnings per share and revenue
On Dec 22, 2025, OKYO reported earnings of -- USD per share (EPS) for Q2 25, -- the estimate of -0.04 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were OKYO Pharma Limited Ordinary Shares's earnings and revenue for the latest quarter Q2 2025?
For Q2 2025, OKYO Pharma Limited Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to OKYO Pharma Limited Ordinary Shares's Q2 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is OKYO Pharma Limited Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for OKYO Pharma Limited Ordinary Shares's next earnings report?
Based on --
analysts, OKYO Pharma Limited Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.